RTP Mobile Logo
Ovarian Cancer Update, Issue 1, 2011
Released March 2011

Featuring interviews with Drs Ursula A Matulonis, Bradley J Monk, Robert L Coleman and William P McGuire. (Text and Audio Content)

CE Disclosures and Faculty Information

  • CME credit is no longer available for this issue


    Management of ovarian cancer (OC) includes optimal surgical debulking followed by postoperative chemotherapy and, in most cases, subsequent medical management when the disease recurs. Although many single-agent and combination chemotherapy regimens have been studied, only recently have antibody and small-molecule growth-inhibitory targeted agents been integrated into the OC research milieu. It is hoped that the results from these trials will lead to the emergence of new therapeutic agents and changes or enhancements in the indications for existing treatment strategies, ultimately improving the duration and quality of life for patients with metastatic OC. To bridge the gap between research and patient care, this issue of Ovarian Cancer Update features one-on-one discussions with leading gynecologic oncology investigators. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical and gynecologic oncologists with the formulation of therapeutic strategies, which in turn facilitates optimal patient care.


    • Explain the rationale for angiogenesis inhibition in the treatment of OC.
    • Summarize data from clinical trials that have evaluated anti-angiogenic agents in the management of OC.
    • Describe how the most recent Phase III clinical trial data may affect the approach to OC.
    • Consider the utility of CA125 levels in monitoring disease progression and making treatment decisions.
    • Recall the rationale for and activity of novel targeted agents under investigation for the treatment of OC.
    • Counsel appropriately selected patients about the availability of ongoing clinical trials in which they may be eligible to participate. 


    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


    Research To Practice designates this educational activity for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.


    This CME activity contains both audio and print components. To receive credit, the participant should listen to the audio MP3s, read the text portion and complete the Post-test and Educational Assessment and Credit Form located on our website at ResearchToPractice.com/OCU210/CME. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr MatulonisConsulting Agreement: Merck and Company Inc; Research Funding: AstraZeneca Pharmaceuticals LP. Dr MonkPaid Research: GlaxoSmithKline, Johnson & Johnson Pharmaceuticals, Sanofi-Aventis; Speakers Bureau: Genzyme Corporation, GlaxoSmithKline, Lilly USA LLC. Dr ColemanAdvisory Committee: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Amgen Inc, AstraZeneca Pharmaceuticals LP, Centocor Ortho Biotech Services LLC, Daiichi Sankyo Inc, Lilly USA LLC, Merck and Company Inc, Nektar; Consulting Agreements: Allos Therapeutics, BiPar Sciences Inc, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline, Lilly USA LLC, Merck and Company Inc, Pfizer Inc, Sanofi-Aventis; Speakers Bureau: Lilly USA LLC. Dr McGuireAdvisory Committee: Genentech BioOncology, ImClone Systems Incorporated, Lilly USA LLC; Consulting Agreement: Bristol-Myers Squibb Company; Paid Research: ImClone Systems Incorporated; Speakers Bureau: GlaxoSmithKline.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium — The Takeda Oncology Company, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Seattle Genetics.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This program is supported by educational grants from Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, Lilly USA LLC and Sanofi-Aventis.

    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2011
    Expiration date: March 2012

    CME credit is no longer available for this issue

Acknowledge and close

Listen to audio:
Ovarian Cancer Update, Issue 1, 2011
Released March 2011

Featuring interviews with Drs Ursula A Matulonis, Bradley J Monk, Robert L Coleman and William P McGuire. (Text and Audio Content)

Read print: